Katherine A. High
Spark Therapeutics (United States) · 362 works · 39,852 citations · h-index 92
Top works
- Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response
- Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
- Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector
- Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
- Recombinant adeno-associated virus for muscle directed gene therapy
- Haemophilia B: database of point mutations and short additions and deletions--second edition
- Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65 -mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial
- Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus
- Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector
- AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
- Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
- Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial
- CD8+ T-cell responses to adeno-associated virus capsid in humans
- In vivo genome editing restores haemostasis in a mouse model of haemophilia
- Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A
- Gene therapy comes of age
- Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
- Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges
- Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy
- Immune responses to AAV vectors: overcoming barriers to successful gene therapy